Full Breakdown
FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome
2/10/2026, 12:29:40 PM
Overview of the Rejection
The U.S. Food and Drug Administration (FDA) has rejected Regenxbio's gene therapy, RGX-121, intended for the treatment of mucopolysaccharidosis type II (MPS II), commonly known as Hunter syndrome. This decision, announced on February 9, 2026, follows a delayed decision deadline and a clinical hold imposed on the therapy due to concerns regarding its clinical trial design and the use of a biomarker as a surrogate endpoint.
Key Concerns Raised by the FDA
The FDA's rejection was influenced by several factors, including the trial's inability to adequately define the patient population and the appropriateness of using a natural history control arm. The agency also expressed skepticism about relying on heparan sulfate, a biomarker, as a surrogate for clinical outcomes. Regenxbio had previously submitted additional data to address these concerns, but the FDA remained unconvinced.
Background on RGX-121 and Related Trials
RGX-121 is designed to replace a malfunctioning gene responsible for Hunter syndrome, which leads to severe physical and cognitive impairments. The therapy was initially accepted for accelerated approval consideration in May 2025. However, the FDA's decision to place RGX-121 on clinical hold was compounded by a separate incident involving RGX-111, another Regenxbio therapy for Hurler syndrome, where a patient developed a brain tumor. Although the FDA acknowledged this incident, it did not cite it as a reason for RGX-121's rejection.
Implications for Patients and Families
The rejection of RGX-121 has significant implications for families affected by Hunter syndrome. Curran Simpson, Regenxbio's president and CEO, described the decision as "devastating" for families awaiting treatment options. The National MPS Society expressed profound concern over the FDA's decision, emphasizing the urgent need for effective therapies for these progressive, life-threatening diseases.
Criticism of the FDA's Approach
Critics, including Regenxbio executives and gene therapy experts, have voiced concerns regarding the FDA's stringent requirements for gene therapy approvals. Vinay Prasad, M.D., head of the FDA's Center for Biologics Evaluation and Research, has previously criticized the reliance on biomarkers over placebo-controlled trials that measure clinical outcomes. This approach has raised questions about the balance between ensuring patient safety and addressing the urgent needs of those with rare diseases.
Future Directions for Regenxbio
In response to the FDA's rejection, Regenxbio plans to resubmit RGX-121 for approval with longer-term data as soon as possible. The company aims to demonstrate the therapy's potential benefits against the backdrop of the severe unmet medical needs associated with Hunter syndrome. Experts like Jim Wilson, a gene therapy pioneer, have highlighted the importance of continuing to develop gene therapies for rare diseases, where the potential benefits may outweigh the risks.
Verbatim Quotes
- “This decision is devastating for the families of boys living with this progressive, life-threatening disease,” — Curran Simpson, President and CEO of Regenxbio
- “Families know the devastating trajectory of this disease all too well and have waited 20 years for new treatment options. They cannot wait any longer.” — Terri Klein, President and CEO of the National MPS Society
The future of RGX-121 remains uncertain, but the rejection underscores the complexities and challenges faced in the development of gene therapies for rare diseases.
